HealthcareServices

Revenue of the Urinary Tract Cancer Market Predicted to Achieve $9.29 Billion by 2030, Driven by 19.5% CAGR

March 3, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the urinary tract cancer market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Urinary Tract Cancer Market?

The urinary tract cancer market has experienced rapid expansion in recent years. It is anticipated to increase from $3.84 billion in 2025 to $4.56 billion in 2026, reflecting a compound annual growth rate (CAGR) of 18.7%. The historical growth of this market is attributable to a surge in smoking-related cancer incidence, heightened exposure to occupational carcinogens, enhancements in cancer diagnostic capabilities, the establishment of more oncology treatment centers, and greater awareness of urinary tract cancers.

The market for urinary tract cancer is projected to experience swift expansion over the coming years. This market is predicted to reach $9.29 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 19.5%. This projected growth is fueled by increased funding for personalized oncology therapies, a greater embrace of immunotherapy methods, the broadening availability of AI-powered diagnostic instruments, an amplified emphasis on early detection initiatives, and progress in minimally invasive cancer surgical techniques. Key developments anticipated during this period encompass a rise in the uptake of targeted cancer treatments, greater utilization of sophisticated diagnostic imaging, deeper incorporation of precision oncology strategies, an increase in diverse treatment modalities, and a heightened priority on identifying cancer early.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13059&type=smp

What Drivers Are Supporting Technological Adoption In The Urinary Tract Cancer Market?

The increasing incidence of bladder cancer is anticipated to fuel expansion in the urinary tract cancer market. Bladder cancer is characterized by the formation of malignant cells within the urinary bladder’s tissues, a hollow pelvic organ that holds urine from the kidneys before excretion. Such elevated prevalence drives an increased need for diagnostic tools, screening techniques, and therapeutic solutions for individuals with urinary tract cancer. As an illustration, a report released in January 2023 by the American Cancer Society Inc., a US-based voluntary cancer awareness organization, indicated that the projected cases of urinary system cancer reached 168,560 in 2023, marking a 2.66% rise from 164,190 in 2022 in the United States. Consequently, the rising occurrence of bladder cancer is set to stimulate the expansion of the urinary tract cancer market.

Which Segments Are Contributing To The Growth Of The Urinary Tract Cancer Market?

The urinary tract cancer market covered in this report is segmented –

1) By Cancer Type: Bladder Cancer, Urethral Cancer, Ureteric And Renal Pelvic Cancer

2) By Treatment: Chemotherapy, Intravesical Therapy, Radiation Therapy, Surgery

3) By Diagnostic Techniques: Cystoscopy, Transurethral Resection Of The Tumor, Imaging Tests, Urine Analyses, Other Diagnostic Techniques

4) By Distribution Channel: Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Bladder Cancer: Transitional Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma

2) By Urethral Cancer: Urethral Carcinoma, Urethral Tumors

3) By Ureteric And Renal Pelvic Cancer: Ureteric Cancer, Renal Pelvic Cancer

Which Trends Are Expected To Influence The Urinary Tract Cancer Market In The Upcoming Years?

Leading companies in the urinary tract cancer market are prioritizing the launch of next-generation therapies, such as antibody-drug conjugate (ADC) and immune-checkpoint inhibitor combination treatments, to achieve more effective and customized outcomes in urothelial carcinoma. These antibody-drug conjugate immune-checkpoint inhibitor combination treatments denote innovative therapeutic regimens that bring together targeted cytotoxic ADCs with checkpoint inhibitors to both eliminate tumor cells and boost immune system activation, thereby enhancing response rates and survival in urinary tract cancers. For instance, in November 2025, Astellas Pharma Inc., a Japan-based healthcare and pharmaceutical company, gained approval from the U.S. Food and Drug Administration (FDA) for PADCEV (enfortumab vedotin-ejfv) + KEYTRUDA (pembrolizumab) for the neoadjuvant and adjuvant management of muscle-invasive bladder cancer. This treatment incorporates a Nectin-4-directed ADC component alongside PD-1 immune-checkpoint blockade, a design intended to reduce recurrence, progression, or death by ~60% compared to surgery alone, and follows a regulatory path with a target action date of April 7, 2026, under the FDA’s Priority Review program.

Who Are The Core Companies Influencing Trends In The Urinary Tract Cancer Market?

Major companies operating in the urinary tract cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck KGaA, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Boehringer Ingelheim GmbH, Incyte Corporation, Seagen Inc., Exelixis Inc., UroGen Pharma Inc., Mersana Therapeutics, Spectrum Pharmaceuticals

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Urinary Tract Cancer Market?

North America was the largest region in the urinary tract cancer market in 2025. The regions covered in the urinary tract cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Urinary Tract Cancer Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13059&type=smp

Browse Through More Reports Similar to the Global Urinary Tract Cancer Market 2026, By The Business Research Company

Urothelial Carcinoma Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report

Adrenocortical Carcinoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/adrenocortical-carcinoma-global-market-report

Bladder Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795